At the WuXi AppTec 2024 performance briefing held today, the company's vice chairman and global chief investment officer Hu Zhengguo said, "We have noticed that the recent U.S. National Security Commission on Emerging Biotechnologies report contains several far-fetched and unfounded allegations involving the company. The company has previously stated publicly that it has never transferred any U.S. customer data or intellectual property to a third party without authorization. We have also communicated with relevant U.S. government agencies to clarify the facts." Note: Recently, the U.S. National Security Commission on Emerging Biotechnologies stated in a radical 215-page report that China's leading biopharmaceutical company WuXi AppTec is "deeply embedded in the U.S. biopharmaceutical supply chain."